<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02084160</url>
  </required_header>
  <id_info>
    <org_study_id>HIS-FU-EX-1213</org_study_id>
    <nct_id>NCT02084160</nct_id>
  </id_info>
  <brief_title>Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation</brief_title>
  <official_title>The Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation; a Retrospective Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exalenz Bioscience LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exalenz Bioscience LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are:

        -  To evaluate the ability of the Methacetin Breath Test (MBT) to detect hepatic
           decompensation events

        -  To evaluate the relationship between liver Biopsy and clinical outcome and show that the
           MBT has a better predictive ability of clinical outcome than liver biopsy.

        -  To evaluate the ability of the MBT to predict each of the individual liver related
           complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Exalenz has previously gathered information in a previous study on patients with chronic
      liver disease including the methacetin breath test. Several years later, the company wishes
      to investigate this group of subjects and see retrospectively if the breath test was a
      predictor of complications related to their liver disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic decompensation event</measure>
    <time_frame>5 years</time_frame>
    <description>Hepatic decompensation is defined as the occurrence of at least one of the following events in the time frame between the last 13C Methacetin Breath Test (MBT) to the time of data collection:
Death (liver related)
Transplantation (cadaveric and living donors)
Ascites
HE (Hepatic Encephalopathy)
Newly diagnosed varices or variceal bleeding
SBP (spontaneous bacterial peritonitis)
HRS (Hepatorenal syndrome)
HCC (hepatocellular carcinoma)
Increase in CTP (Child Turcotte Pugh) Score by 3 points
Increase in MELD score by 5 points</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">414</enrollment>
  <condition>Chronic Liver Disease</condition>
  <arm_group>
    <arm_group_label>CLD from HIS-EX-408</arm_group_label>
    <description>Chronic liver disease subjects from previous Exalenz trial &quot;HIS-EX-408&quot;</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic liver disease subjects from previous Exalenz trial &quot;HIS-EX-408&quot;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects that aere enrolled in the previous Exalenz trial HIS-EX-408

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meir Mizrachi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Avraham Hershkowitz, MSc</last_name>
    <phone>+972-8-9737513</phone>
    <email>avrahamh@exalenz.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Reuben, MD</last_name>
      <phone>843-367-8927</phone>
      <email>reubena@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Adrian Reuben, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Origanzation</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2014</study_first_submitted>
  <study_first_submitted_qc>March 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2014</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

